Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 10:54 PM
Ignite Modification Date:
2025-12-24 @ 10:54 PM
NCT ID:
NCT07282769
Brief Summary:
This research study is testing the effectiveness and safety of semaglutide (Wegovy) in people with trichotillomania, also known as hair-pulling disorder.
Detailed Description:
The goal of the proposed study is to evaluate the efficacy and safety of semaglutide in individuals with trichotillomania. The hypothesis to be tested is that semaglutide will reduce urges to pull hair and pulling behavior and will be well tolerated in participants with trichotillomania. The proposed study will provide needed pilot data on the treatment of a disabling disorder that currently lacks available options for pharmacological treatment.
The investigators will conduct an open-label pharmacotherapy trial in 10 individuals with trichotillomania. Participants with trichotillomania will be started and continued on medication during an 8-week treatment phase. The study will be the first to use a once weekly Glucagon-like peptide 1 (GLP-1) receptor agonist pharmacological intervention to target urges in trichotillomania and thereby has the potential to set a new standard of care for a range of compulsive behaviors.
Study:
NCT07282769
Study Brief:
Protocol Section:
NCT07282769